New targets for mucosal healing and therapy in inflammatory bowel diseases

Mucosal Immunology

Volumn 7, Issue 1, 2014, Pages 6-19

  Neurath, M F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4BETA7 INTEGRIN; AMG 139; ANRUKINZUMAB; CYTOKINE; ETROLIZUMAB; FINGOLIMOD; GOLIMUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTEGRIN; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 23 ANTIBODY; INTERLEUKIN 6 RECEPTOR ANTIBODY; JANUS KINASE INHIBITOR; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; SMAD7 ANTISENSE; STAT PROTEIN; TOCILIZUMAB; TOFACITINIB; TOLL LIKE RECEPTOR 9; TRALOKINUMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VEDOLIZUMAB; VIDOFLUDIMUS;

ADAPTIVE IMMUNITY; CELL THERAPY; DRUG RESPONSE; DRUG TARGETING; HEALING; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA; MUCOSA INFLAMMATION; MUCOSAL HEALING; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REMISSION; RESECTION FREE SURVIVAL; REVIEW; WORM EGG;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, MONOCLONAL; CELL ADHESION; CYTOKINES; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MICROBIOTA; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTORS; WOUND HEALING;

EID: 84890916350     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2013.73     Document Type: Review

References (194)

1. Danese,S & Fiocchi, C. Ulcerative colitis. N. Engl. J. Med. 365, 1713-1725 (2011).
2. Neurath, M.F., Finotto, S &Glimcher, L.H. The role of Th1/Th2 polarization in mucosal immunity. Nat. Med. 8, 567-573 (2002).
3. Baumgart, D.C. & Sandborn, W.J. Crohn's disease. Lancet 380, 1590-1605 (2012).
4. Peyrin-Biroulet, L, Loftus, E.V. Jr, Colombel, J.F. & Sandborn, W.J. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm. Bowel Dis 17, 471-478 (2011).
5. Bernstein, C.N., Blanchard, J.F., Kliewer, E & Wajda, A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91, 854-862 (2001).
6. Foersch, S, Waldner, M.J. & Neurath, M.F. Colitis and colorectal cancer. Dig. Dis. 30, 469-476 (2012).
7. Hommes, D, Colombel, J.F., Emery, P, Greco, M & Sandborn, W.J. Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life. J. Crohn's Colitis 6(Suppl 2), S224-S234 (2012).
8. Neurath, M.F. & Travis, S.P. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 61, 1619-1635 (2012).
9. Schnitzler, F. et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm. Bowel Dis. 15, 1295-1301 (2009).
10. Colombel, J.F. et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 141, 1194-1201 (2011).
11. Froslie, K.F., Jahnsen, J, Moum, B.A. & Vatn, M.H. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133, 412-422 (2007).
12. Pineton de Chambrun, G, Peyrin-Biroulet, L, Lemann,M& Colombel, J.F. Clinical implications of mucosal healing for the management of IBD. Nat. Rev. Gastroenterol. Hepatol. 7, 15-29 (2010).
13. Rubin, D.T. We once were blind and now we see: Is it time to treat ulcerative colitis to achieve mucosal healing? Clin. Gastroenterol Hepatol 9, 456-457 (2011).
14. Colombel, J.F. et al. Adalimumab induces deep remission in patients with Crohn's disease. Clin. Gastroenterol. Hepatol., in press (2013).
15. Krishnan, K, Arnone, B & Buchman, A. Intestinal growth factors: potential use in the treatment of inflammatory bowel disease and their role in mucosal healing. Inflamm. Bowel Dis 17, 410-422 (2011).
16. Paclik, D, Lohse, K,Wiedenmann, B, Dignass, A.U. & Sturm, A. Galectin- 2 and -4, but not galectin-1, promote intestinal epithelial wound healing in vitro through a TGF-beta-independentmechanism. Inflamm. BowelDis 14, 1366-1372 (2008).
17. Sturm, A & Dignass, A.U. Epithelial restitution and wound healing in inflammatory bowel disease. World J. Gastroenterol 14, 348-353 (2008).
18. Dignass, A.U. & Podolsky, D.K. Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor beta. Gastroenterology 105, 1323-1332 (1993).
19. Dignass, A, Lynch-Devaney, K,Kindon,H, Thim, L & Podolsky,D.K. Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway. J. Clin. Invest. 94, 376-383 (1994).
20. Hall, A. Rho GTPases and the control of cell behaviour. Biochem. Soc. Trans. 33 (Part 5), 891-895 (2005).
21. Moyer, R.A., Wendt, M.K., Johanesen, P.A., Turner, J.R. & Dwinell, M.B. Rho activation regulates CXCL12 chemokine stimulated actin rearrangement and restitution in model intestinal epithelia. Lab. Invest. 87, 807-817 (2007).
22. Vongsa, R.A., Zimmerman, N.P. & Dwinell, M.B. CCR6 regulation of the actin cytoskeleton orchestrates human beta defensin-2- and CCL20-mediated restitution of colonic epithelial cells. J. Biol. Chem. 284, 10034-10045 (2009).
23. Iizuka, M& Konno, S. Wound healing of intestinal epithelial cells. World J. Gastroenterol. 17, 2161-2171 (2011).
24. Dignass, A.U., Stow, J.L. & Babyatsky, M.W. Acute epithelial injury in the rat small intestine in vivo is associated with expanded expression of transforming growth factor alpha and beta. Gut 38, 687-693 (1996).
25. Pickert, G. et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J. Exp. Med. 206, 1465-1472 (2009).
26. Nenci, A. et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446, 557-561 (2007).
27. Grivennikov, S. et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103-113 (2009).
28. Becker, C. et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21, 491-501 (2004).
29. Seno, H, Miyoshi, H, Brown, S.L., Geske, M.J., Colonna, M & Stappenbeck, T.S. Efficient colonic mucosal wound repair requires Trem2 signaling. Proc. Natl. Acad. Sci. USA 106, 256-261 (2009).
30. Goretsky, T. et al. P53 mediates TNF-induced epithelial cell apoptosis in IBD. Am. J. Pathol. 181, 1306-1315 (2012).
31. Gilbert, S. et al. Enterocyte STAT5 promotes mucosal wound healing via suppression of myosin light chain kinase-mediated loss of barrier function and inflammation. EMBO Mol. Med. 4, 109-124 (2012).
32. Han, X. et al. Regulation of intestinal barrier function by signal transducer and activator of transcription 5b. Gut 58, 49-58 (2009).
33. Goke, M, Kanai, M & Podolsky, D.K. Intestinal fibroblasts regulate intestinal epithelial cell proliferation via hepatocyte growth factor. Am. J. Physiol. 274 (Part 1), G809-G818 (1998).
34. Su, L. et al. TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis. Gastroenterology 145, 407-415 (2013).
35. Bernasconi, E. et al. Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing. Inflamm. Bowel Dis. 16, 428-441 (2010).
36. Huebener, P & Schwabe, R.F. Regulation of wound healing and organ fibrosis by toll-like receptors. Biochim Biophys. Acta 1832, 1005-1017 (2013).
37. Podolsky,D.K., Gerken, G, Eyking, A & Cario, E. Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. Gastroenterology 137, 209-220 (2009).
38. Ey, B, Eyking, A, Gerken, G, Podolsky,D.K. &Cario, E. TLR2 mediates gap junctional intercellular communication through connexin-43 in intestinal epithelial barrier injury. J. Biol. Chem. 284, 22332-22343 (2009).
39. Fukata, M. et al. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G1055-G1065 (2005).
40. Lee, J. et al. Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat. Cell. Bio.l 8, 1327-1336 (2006).
41. Lee, J, Mo, J.H., Shen, C, Rucker, A.N. & Raz, E. Toll-like receptor signaling in intestinal epithelial cells contributes to colonic homoeostasis. Curr. Opin. Gastroenterol. 23, 27-31 (2007).
42. Rose,W.A. II, Sakamoto, K & Leifer, C.A. TLR9 is important for protection against intestinal damage and for intestinal repair. Scientific Rep. 2, 574 (2012).
43. Katakura, K, Lee, J, Rachmilewitz, D, Li, G, Eckmann, L & Raz, E. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J. Clin. Invest. 115, 695-702 (2005).
44. Rachmilewitz, D. et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126, 520-528 (2004).
45. Rachmilewitz, D. et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 122, 1428-1441 (2002).
46. Wehkamp, J. et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc. Natl. Acad. Sci. USA 102, 18129-18134 (2005).
47. Ho, S.B. et al. Cysteine-rich domains of muc3 intestinal mucin promote cell migration, inhibit apoptosis, and accelerate wound healing. Gastroenterology 131, 1501-1517 (2006).
48. Otte, J.M. et al. Human beta defensin 2 promotes intestinal wound healing in vitro. J. Cell. Biochem. 104, 2286-2297 (2008).
49. Pickard, K.M., Bremner, A.R., Gordon, J.N. & MacDonald, T.T.Microbial- gut interactions in health and disease. Immune responses. Best Pract. Res. Clin. Gastroenterol. 18, 271-285 (2004).
50. Hering, N.A., Fromm, M & Schulzke, J.D. Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. J. Physiol. 590 (Part 5), 1035-1044 (2012).
51. McGuckin, M.A., Eri, R, Simms, L.A., Florin, T.H. & Radford-Smith, G. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm. Bowel Dis. 15, 100-113 (2009).
52. John, L.J., Fromm, M & Schulzke, J.D. Epithelial barriers in intestinal inflammation. Antioxidants Redox Signal. 15, 1255-1270 (2011).
53. Fischer, A, Gluth, M, Pape, U.F., Wiedenmann, B, Theuring, F & Baumgart, D.C. Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-alpha on tight junction proteins and signaling pathways in intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 304, G970-G979 (2013).
54. Zeissig, S. et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut 53, 1295-1302 (2004).
55. Heller, F. et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129, 550-564 (2005).
56. Boltin, D, Perets, T.T., Vilkin, A & Niv, Y. Mucin function in inflammatory bowel disease: an update. J. Clin. Gastroenterol. 47, 106-111 (2013).
57. Sheng, Y.H., Hasnain, S.Z., Florin, T.H. & McGuckin, M.A. Mucins in inflammatory bowel diseases and colorectal cancer. J. Gastroenterol. Hepatol. 27, 28-38 (2012).
58. Johansson, M.E., Larsson, J.M. & Hansson, G.C. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc. Natl. Acad. Sci. USA 108(Suppl 1), 4659-4665 (2011).
59. Hansson, G.C. & Johansson, M.E. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Gut Microbes 1, 51-54 (2010).
60. Dorofeyev, A.E., Vasilenko, I.V., Rassokhina, O.A. & Kondratiuk, R.B. Mucosal barrier in ulcerative colitis and Crohn's disease. Gastroenterol. Res. Pract. 2013, 431231 (2013).
61. Stremmel, W, Hanemann, A, Ehehalt, R, Karner, M & Braun, A. Phosphatidylcholine (lecithin) and the mucus layer: evidence of therapeutic efficacy in ulcerative colitis? Dig. Dis. 28, 490-496 (2010).
62. Stremmel, W, Merle, U, Zahn, A, Autschbach, F, Hinz, U & Ehehalt, R. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 54, 966-971 (2005).
63. Gunther, C. et al. Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature 477, 335-339 (2011).
64. Salzman, N.H., Ghosh, D, Huttner, K.M., Paterson, Y & Bevins, C.L. Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature 422, 522-526 (2003).
65. Kruis, W. et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53, 1617-1623 (2004).
66. Gersemann, M, Wehkamp, J & Stange, E.F. Innate immune dysfunction in inflammatory bowel disease. J. Intern. Med. 271, 421-428 (2012).
67. Hofmann, C. et al. T cell-dependent protective effects of CpG motifs of bacterial DNA in experimental colitis are mediated by CD11c+ dendritic cells. Gut 59, 1347-1354 (2010).
68. Musch, E. et al. Topical treatment with the Toll-like receptor agonist DIMS0150 has potential for lasting relief of symptoms in patients with chronic active ulcerative colitis by restoring glucocorticoid sensitivity. Inflamm. Bowel Dis. 19, 283-292 (2013).
69. Prantera, C, Lochs, H, Grimaldi, M, Danese, S, Scribano, M.L. & Gionchetti, P. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 142, 473-481 e474 (2012).
70. Prantera, C. et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment. Pharmacol. Therap. 23, 1117-1125 (2006).
71. Papi, C, Spurio, F.F., Margagnoni, G & Aratari, A. Randomized controlled trials in prevention of postsurgical recurrence in Crohn's disease. Rev. Recent Clin. Trials 7, 307-313 (2012).
72. Gardet, A & Xavier, R.J. Commonalleles that influence autophagy andthe risk for inflammatory bowel disease. Curr. Opin. Immunol. 24, 522-529 (2012).
73. Kuballa, P, Nolte, W.M.,Castoreno, A.B. & Xavier, R.J. Autophagy and the immune system. Annu. Rev. Immunol. 30, 611-646 (2012).
74. Chassaing, B. et al. Crohn disease-associated adherent-invasive E. coli bacteria target mouse and human Peyer's patches via long polar fimbriae. J. Clin. Invest. 121, 966-975 (2011).
75. Scharl, M & Rogler, G. Inflammatory bowel disease: dysfunction of autophagy?. Dig. Dis. 30(Suppl 3), 12-19 (2012).
76. Bringer, M.A., Billard, E, Glasser, A.L., Colombel, J.F. & Darfeuille- Michaud, A. Replication of Crohn's disease-associated AIEC within macrophages is dependent on TNF-alpha secretion. Lab. Invest. 92, 411-419 (2012).
77. Flammer, J.R. & Rogatsky, I. Minireview: glucocorticoids in autoimmunity: unexpected targets and mechanisms. Mol. Endocrinol. 25, 1075-1086 (2011).
78. Kornbluth, A, Present, D.H., Lichtiger, S & Hanauer, S. Cyclosporin for severe ulcerative colitis: a user's guide. Am. J. Gastroenterol. 92, 1424-1428 (1997).
79. Lichtiger, S & Present, D.H. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 336, 16-19 (1990).
80. Feagan, B.G. et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N. Engl. J. Med. 342, 1627-1632 (2000).
81. Feagan, B.G. et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N.Engl. J. Med. 332, 292-297 (1995).
82. Neurath, M.F. et al. Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): amechanism formethotrexate-mediated immunosuppression. Clin. Exp. Immunol. 115, 42-55 (1999).
83. Hildner, K. et al. Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis. Clin. Exp. Immunol. 118, 137-146 (1999).
84. Kaminuma, O. Selective inhibitors of nuclear factor of activated T cells: potential therapeutic drugs for the treatment of immunological and inflammatory diseases. Inflamm. Allergy DrugTargets 7, 35-40 (2008).
85. Fric, J, Zelante, T,Wong, A.Y.,Mertes, A, Yu, H.B. & Ricciardi-Castagnoli, P. NFAT control of innate immunity. Blood 120, 1380-1389 (2012).
86. Daniel, C, Gerlach, K, Vath, M, Neurath, M.F. & Weigmann, B. Nuclear factor of activated Tcells - a transcription factor family as critical regulator in lung and colon cancer. Int. J. Cancer, (in press) (2013).
87. Weigmann, B & Neurath, M.F. Selective targeting of activated T cells in chronic intestinal inflammation. Gut 58, 747-748 (2009).
88. Tiede, I. et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 111, 1133-1145 (2003).
89. Poppe, D. et al. Azathioprine suppresses ezrin-radixin-moesin-dependent Tcell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J. Immunol. 176, 640-651 (2006).
90. Scheller, J, Chalaris, A, Garbers,C& Rose-John, S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol. 32, 380-387 (2011).
91. Wajant, H, Pfizenmaier, K & Scheurich, P. Tumor necrosis factor signaling. Cell Death Differ. 10, 45-65 (2003).
92. Colombel, J.F. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl J. Med. 362, 1383-1395 (2010).
93. Colombel, J.F. et al. Adalimumab formaintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132, 52-65 (2007).
94. Hanauer, S.B. et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130, 323-333. quiz 591 (2006).
95. Evans,A.T. & Lee, S.D. Areview and expert opinion of the use of certolizumab for Crohn's disease. Expert Opin. Biol. Ther. 12, 363-370 (2012).
96. Rutgeerts, P, Vermeire, S & Van Assche, G. Predicting the response to infliximab from trough serum levels. Gut 59, 7-8 (2010).
97. Present, D.H. Review article: the efficacy of infliximab in Crohn's disease - healing of fistulae. Aliment. Pharmacol. Therap. 13(Suppl 4), 23-28. discussion 38 (1999).
98. Hanauer, S.B. et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359, 1541-1549 (2002).
99. Sandborn, W.J. et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology, (in press) (2013).
100. Sandborn, W.J. et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology, (in press) (2013).
101. Gecse, K.B. et al. Biosimilars in IBD: hope or expectation? Gut 62, 803-807 (2013).
102. Vandenbroucke, K. et al. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 3, 49-56 (2010).
103. Assier, E. et al. Modulation of anti-tumor necrosis factor alpha (TNF-alpha) antibody secretion in mice immunized with TNF-alpha kinoid. Clin. Vaccine Immunol. 19, 699-703 (2012).
104. Danese, S, Colombel, J.F., Peyrin-Biroulet, L, Rutgeerts, P & Reinisch,W. Review article: the role of anti-TNF in the management of ulcerative colitis - past, present and future. Aliment. Pharmacol. Therap. 37, 855-866 (2013).
105. Danese, S, Fiorino, G & Reinisch, W. Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy. Aliment. Pharmacol. Therap. 34, 1-10 (2011).
106. Sandborn, W.J. & Hanauer, S.B. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm. Bowel Dis. 5, 119-133 (1999).
107. Colombel, J.F. et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm. Bowel Dis. 15, 1308-1319 (2009).
108. Eser, A, Primas, C & Reinisch, W. Drug monitoring of biologics in inflammatory bowel disease. Curr. Opin. Gastroenterol. 29, 391-396 (2013).
109. Vos,A.C.,Wildenberg,M.E.,Duijvestein,M,Verhaar,A.P., vandenBrink,G.R. & Hommes, D.W. Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology 140, 221-230 (2011).
110. Vos, A.C. et al. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflamm. Bowel Dis. 18, 401-408 (2012).
111. Van den Brande, J.M. et al. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut 56, 509-517 (2007).
112. Atreya, R. et al. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14(+)macrophages. Gastroenterology 141, 2026-2038 (2011).
113. Mitoma, H. et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 128, 376-392 (2005).
114. Van den Brande, J.M. et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124, 1774-1785 (2003).
115. Sandborn, W.J. et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121, 1088-1094 (2001).
116. Atreya, R. et al. Prediction of anti-TNF antibody responses in crohn's disease by endoscopic molecular imaging in vivo. Gastroenterology 142 (Suppl), S535 (2012).
117. Perrier, C. et al. Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis. Inflamm. Bowel Dis. 19, 246-253 (2013).
118. Lethaby, A, Lopez-Olivo, M.A., Maxwell, L, Burls, A, Tugwell, P & Wells, G.A. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. 5, CD004525 (2013).
119. Papp, K.A. et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366, 1181-1189 (2012).
120. Plushner, S.L. Tocilizumab: an interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis. Ann. Pharmacother. 42, 1660-1668 (2008).
121. Fuss, I.J. et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157, 1261-1270 (1996).
122. Monteleone, I, Pallone, F & Monteleone, G. Th17-related cytokines: new players in the control of chronic intestinal inflammation.BMCMed. 9, 122 (2011).
123. De Nitto, D, Sarra, M, Cupi, M.L., Pallone, F & Monteleone, G. Targeting IL-23 and Th17-cytokines in inflammatory bowel diseases. Curr. Pharm. Des. 16, 3656-3660 (2010).
124. Kleinschek, M.A. et al. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J. Exp. Med. 206, 525-534 (2009).
125. Reinisch,W. et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm. Bowel Dis. 16, 233-242 (2010).
126. Reinisch, W. et al. A dose escalating, placebo controlled, double blind, single dose andmultidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 55, 1138-1144 (2006).
127. Leppkes, M. et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 136, 257-267 (2009).
128. Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693-1700 (2012).
129. Hovhannisyan, Z, Treatman, J, Littman, D.R. & Mayer, L. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology 140, 957-965 (2011).
130. Sands,B.E. et al. Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. Gastroenterology 143, 356-364 e351 (2012).
131. Atreya, R & Neurath, M.F. Signaling molecules: the pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer. Curr. Drug Targets 9, 369-374 (2008).
132. Atreya, R. et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat. Med. 6, 583-588 (2000).
133. Ito, H. et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126, 989-996. discussion 947 (2004).
134. Jones, S.A., Scheller, J & Rose-John, S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 121, 3375-3383 (2011).
135. Siegmund, B. et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281, R1264-R1273 (2001).
136. Stolfi, C. et al. Involvement of interleukin-21 in the regulation of colitisassociated colon cancer. J. Exp. Med. 208, 2279-2290 (2011).
137. Cox, J.H., Kljavin, N.M., Ramamoorthi, N, Diehl, L, Batten, M & Ghilardi, N. IL-27 promotes Tcell-dependent colitis through multiple mechanisms. J. Exp. Med. 208, 115-123 (2011).
138. Heller, F, Fuss, I.J., Nieuwenhuis, E.E., Blumberg, R.S. & Strober, W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 17, 629-638 (2002).
139. Kawashima, R. et al. Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice - a pathway associated with ulcerative colitis. Gastroenterology 141, 2119-2129 e2118 (2011).
140. Fuss, I.J. & Strober,W. The role of IL-13 andNKTcells in experimental and human ulcerative colitis. Mucosal Immunol 1(Suppl 1), S31-S33 (2008).
141. Fuss, I.J. et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest. 113, 1490-1497 (2004).
142. Sandborn,W.J. et al. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 143, 62-69 e64 (2012).
143. Sandborn, W.J. et al. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut 59, 1485-1492 (2010).
144. Mayer, L. et al. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut, (in press) (2013).
145. Dotan, I. et al. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease. Gut 59, 760-766 (2010).
146. Fournier, P & Schirrmacher, V. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future. BioDrugs 27, 35-53 (2013).
147. Neurath, M.F., Fuss, I, Kelsall, B.L., Stuber, E & Strober, W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182, 1281-1290 (1995).
148. Davidson, N.J., Hudak, S.A., Lesley, R.E., Menon, S, Leach, M.W. & Rennick, D.M. IL-12 but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J. Immunol. 161, 3143-3149 (1998).
149. Fuss, I.J., Marth, T, Neurath, M.F., Pearlstein, G.R., Jain, A & Strober, W. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 117, 1078-1088 (1999).
150. Hue, S. et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med. 203, 2473-2483 (2006).
151. Monteleone, I, Sarra, M, Pallone, F & Monteleone, G. Th17-related cytokines in inflammatory bowel diseases: friends or foes? Curr. Mol. Med. 12, 592-597 (2012).
152. Valatas, V, He, J, Rivollier, A, Kolios, G, Kitamura, K & Kelsall, B.L. Hostdependent control of early regulatory and effector T-cell differentiation underlies the genetic susceptibility of RAG2-deficient mouse strains to transfer colitis. Mucosal Immunol. 6, 601-611 (2013).
153. Wirtz, S. et al. Cutting edge: chronic intestinal inflammation in STAT-4 transgenic mice: characterization of disease and adoptive transfer by TNF- plus IFN-gamma-producing CD4+ Tcells that respond to bacterial antigens. J. Immunol. 162, 1884-1888 (1999).
154. Fuss, I.J. et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm. Bowel Dis. 12, 9-15 (2006).
155. Mannon, P.J. et al. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351, 2069-2079 (2004).
156. Sandborn, W.J. et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-tosevere Crohn's disease. Gastroenterology 135, 1130-1141 (2008).
157. Sandborn,W.J. et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 367, 1519-1528 (2012).
158. Sandborn, W.J. et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367, 616-624 (2012).
159. Liao,W, Lin, J.X. & Leonard,W.J. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr. Opin. Immunol. 23, 598-604 (2011).
160. Davidson, N.J. et al. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J. Exp. Med. 184, 241-251 (1996).
161. Erdman, S.E. et al. CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res. 63, 6042-6050 (2003).
162. Fedorak, R.N. et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119, 1473-1482 (2000).
163. Herrlinger, K.R. et al. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am. J. Gastroenterol. 101, 793-797 (2006).
164. Braat, H. et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 4, 754-759 (2006).
165. Hayashi, A. et al. A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. Cell Host Microbe 13, 711-722 (2013).
166. Mizoguchi, A. Healing of intestinal inflammation by IL-22. Inflamm. Bowel Dis. 18, 1777-1784 (2012).
167. Leung, J.M. et al. IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue. Mucosal Immunol., (in press) (2013).
168. Wirtz, S, Billmeier, U, McHedlidze, T, Blumberg, R.S. & Neurath, M.F. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology 141, 1875-1886 (2011).
169. Fahlen, L. et al. Tcells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J. Exp. Med. 201, 737-746 (2005).
170. Uhlig, H.H. et al. Characterization of Foxp3+CD4+CD25+ and IL-10- secreting CD4+CD25+ T cells during cure of colitis. J. Immunol. 177, 5852-5860 (2006).
171. Izcue, A, Coombes, J.L. & Powrie, F. Regulatory Tcells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol. Rev. 212, 256-271 (2006).
172. Fantini, M.C. et al. Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut 55, 671-680 (2006).
173. Desreumaux, P. et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology 143, 1207-1217 e1201-1202 (2012).
174. Shi, Y & Massague, J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685-700 (2003).
175. Monteleone, G, Boirivant, M, Pallone, F & Mac Donald, T.T. TGF-beta1 and Smad7 in the regulation of IBD. Mucosal Immunol. 1(Suppl 1), S50-S53 (2008).
176. Boirivant, M. et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology 131, 1786-1798 (2006).
177. Fantini, M.C. et al. Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology 136, 1308-1316. e1301-1303 (2009).
178. Monteleone, G. et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol. Ther. 20, 870-876 (2012).
179. Weinstock, J.V. Autoimmunity: the worm returns. Nature 491, 183-185 (2012).
180. Summers, R.W., Elliott, D.E., Urban, J.F. Jr., Thompson, R.A. & Weinstock, J.V. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 128, 825-832 (2005).
181. Summers, R.W., Elliott, D.E., Urban, J.F. Jr., Thompson, R & Weinstock, J.V. Trichuris suis therapy in Crohn's disease. Gut 54, 87-90 (2005).
182. Cantacessi, C. et al. The transcriptome of Trichuris suis - first molecular insights into a parasite with curative properties for key immune diseases of humans. PLoS One 6, e23590 (2011).
183. Podolsky, D.K. Selective adhesion-molecule therapy and inflammatory bowel disease - a tale of Janus? N. Engl. J. Med. 353, 1965-1968 (2005).
184. Podolsky, D.K. et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest 92, 372-380 (1993).
185. Sandborn,W.J. et al. Natalizumab induction andmaintenance therapy for Crohn's disease. N. Engl. J. Med. 353, 1912-1925 (2005).
186. Van Assche, G. et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353, 362-368 (2005).
187. Gledhill, T & Bodger, K. New and emerging treatments for ulcerative colitis: a focus on vedolizumab. Biologics 7, 123-130 (2013).
188. Parikh, A. et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm. Bowel Dis. 18, 1470-1479 (2012).
189. Rutgeerts, P.J. et al. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut 62, 1122-1130 (2012).
190. Thomas, S & Baumgart, D.C. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology 20, 1-18 (2012).
191. Papadakis, K.A. et al. CC chemokine receptor 9 expression defines a subset of peripheral blood lymphocytes with mucosal T cell phenotype and Th1 or T-regulatory 1 cytokine profile. J. Immunol. 171, 159-165 (2003).
192. Bamias, G, Clark, D.J. & Rivera-Nieves, J. Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease. Curr. Drug Targets advance online publication, 25 April 2013 (e-pub ahead of print).
193. Neurath, M.F. et al. The transcription factor T-bet regulates mucosal Tcell activation in experimental colitis and Crohn's disease. J. Exp. Med. 195, 1129-1143 (2002).
194. Kobayashi, T. et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 57, 1682-1689 (2008).